DOCSLIB.ORG

For Genes Stadtmans by LISA YUAN, NIDDK by LAURA STEPHENSON CARTER

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
For Genes Stadtmans by LISA YUAN, NIDDK by LAURA STEPHENSON CARTER NATIONAL INSTITUTES OF HEALTH • OFFICE OF THE DIRECTOR | VOLUME 27 ISSUE 1 • JANUARY-FEBRUARY 2019 The Merry Band of Creating a “Spellchecker” for Genes Stadtmans BY LISA YUAN, NIDDK BY LAURA STEPHENSON CARTER Meet 15 more investigators who have become part of the Earl Stadtman Tenure-Track Investigator Program, which was launched in 2009 and named for the legendary biochemist who worked at NIH for 50 years. The program aims to recruit a diverse group of scientists with interests across the biomedical-research spectrum. Seven of the Stadtmans focus on cancer research and work in the National Cancer Institute. Two work in the National Heart, Lung, and Blood Institute ERNESTO DEL AGUILA III, NHGRI and both have dual appointments with other institutes. Another hails from the National Institute of Environmental Health Sciences in Research Triangle Park in North Carolina and holds a dual appointment with another institute. The other five Stadtmans each represent a different institute: National Institute CRISPR-Cas9 is a customizable tool that lets scientists cut and insert small pieces of DNA at precise areas along a DNA of Diabetes and Digestive and Kidney strand. Lothar Hennighausen’s team has led the way in describing the extent of unwanted molecular scarring that the Diseases; National Institute of Biomedical CRISPR-Cas9 technique can cause at target sites of mammalian genomes. Imaging and Bioengineering; National Eye Institute; National Institute on Imagine a pair of molecular scissors that could snip and tweak sections of Aging; and the Eunice Kennedy Shriver the genetic alphabet. Or tweezers that could pluck one letter and replace it with National Institute of Child Health and another. These tools have become a reality in recent years, allowing scientists to correct Human Development. “misspellings” in the genetic code. And one NIH lab is taking full advantage of this. Get to know them a bit. You’ll learn CONTINUED ON PAGE 16 what their research is, what discoveries they’ve made, how they got interested CONTENTS in science, and even a few secrets. And FEATURES • |1, 10| The Merry Band of Stadtmans |1| Creating a “Spellchecker” for Genes if you go online, you’ll learn even more: |3| NIH Distinguished Scholars Program |14| Alejandro Sánchez Alvarado: How Flatworms https://irp.nih.gov/catalyst/v27i1/ Regenerate |18| 2018 Obits |19| America’s Cancer Doctor: Alan Rabson the-merry-band-of-stadtmans. DEPARTMENTS • |2| DDIR: A New Centralized IRB |4, 5| Training Page: Fellows Editorial CONTINUED ON PAGE 10 Board; Breaking Through the Petri Dish Lid |6, 7| News You Can Use: Office of Patient Recruitment; NIH Library Services |8| Research Briefs |15| The SIG Beat |17| Abbreviations; Take the Survey |20| NIH in History: Celebrating Nobel Laureate Christian B. Anfinsen FROM THE DEPUTY DIRECTOR FOR INTRAMURAL RESEARCH A New Centralized Institutional Review Board BY MICHAEL GOTTESMAN, DDIR, AND JONATHAN GREEN, OD As you almost certainly have Research Subjects Review Board Office are several provisions that will affect heard by now, the NIH Intramural at the University of Rochester (Rochester, all investigators including changes to Research Program is in the process New York). the informed-consent process, new of centralizing and consolidating the We are close to completing one step of exemptions, and the elimination of Institutional Review Board (IRB) the centralization process: the migration of continuing review for some minimal-risk system. The 12 independent IRBs protocol information from three different research. will be transitioning to one IRB information-technology systems to one To ensure compliance with the new office, and the three different protocol central-tracking and data-management rule, all new studies slated for initial and data-management systems are system—iRIS, short for integrated- approval on or after January 21, 2019, will being consolidated into one. The goal research information system. be processed by the IRBO and reviewed is to improve the consistency of IRB The IRBO will handle all protocol by the NIH Intramural IRB. All studies review and the overall efficiency of submissions for the intramural research approved before January 21 will remain the IRB system. program; make exempt and nonhuman under the old rule and do not need to This type of IRB reorganization has subjects determinations; and conduct comply with any of the revised Common been deployed successfully at universities expedited reviews of minimal-risk Rule requirements. Amendments and around the country not only to enhance research. The office will conduct in-depth continuing reviews will continue to be human-research protections but also to pre-reviews before sending protocols to handled by the current NIH IRBs. Over benefit principal investigators on clinical a new, central NIH Intramural IRB the course of the next several months, we protocols by ensuring an efficient review committee. During this process, we will transition each of the committees into process. The IRB reorganization will also hope to identify and address any issues the new structure. ensure that we are compliant with the that could delay approval. The pre-review We are confident that the new IRB revised Common Rule (also known as will be done by trained professional system will be an improvement for the Federal Policy for the Protection of IRB analysts with consultation from everyone. For investigators, there should Human Subjects), which becomes effective IRB chairs, human-research protection be greater consistency in IRB review and on January 21, 2019. program leadership, and other experts more efficient turnaround times. For IRB We have brought on two new team as needed. members, meetings will be shorter with members to lead this effort, Jonathan The new NIH Intramural IRB— fewer agenda items, allowing for greater Green as the director of the Office of consisting of all current NIH IRB preparation and participation. Human Subjects Research Protections members—will use an innovative “flexible We thank you in advance for your (OHSRP) and Tiffany Gommel as the IRB” model and will begin meeting in patience and understanding as we director of IRB Operations (IRBO), a January 2019. Panels will meet multiple undertake this initiative. There will almost new centralized administrative office. times per week, conducting shorter certainly be some bumps in the road as Jonathan joins us from Washington meetings with fewer agenda items than we get going, but with your help we will University School of Medicine in are on current committee schedules. In achieve smooth sailing soon. St. Louis, where he was professor of this way, once ready, protocols can be medicine, pathology, and immunology, scheduled for meetings with less delay. Jonathan Green, M.D., M.B.A., is associate dean for Human Studies, and The revisions to the Common Rule the director of the Office of Human executive chair of the university’s IRB. constitute the first substantive changes Subjects Research Protections. For more Tiffany was executive director of the since its publication in 1991. There information, go to irbo.nih.gov. 2 THE NIH CATALYST JANUARY-FEBRUARY 2019 FEATURE NIH Distinguished Scholars Program BY CARL HASHIMOTO, OD CHIA CHI CHARLIE CHANG CHARLIE CHI CHIA NIH Distinguished Scholars Program participants gathered for an inaugural meeting in the fall. Front row (from left): DSP scholars Joel Vega-Rodriguez, Joana Vidigal, Eric Calvo, Sadhana Jackson, Hugo Tejeda, and Paule Joseph; and Director of Research Workforce Development Roland Owens. Back row (from left): DSP scholar Freddy Escorcia; Deputy Director for Intramural Research Michael Gottesman; senior investigators and mentors Julie Segre, Veronica Alvarez, and John Tisdale; NIH Director Francis Collins; Chief Officer for Scientific Workforce Diversity Hannah Valantine; Senior Advisor for Faculty Development Carl Hashimoto; and DSP scholars Nida Sen, Faustine Williams, Catherine Cukras, and Sherine El-Toukhy (missing DSP scholars: Jennifer Jones and Joseph Rodriguez). As part of an effort to enhance research and in promoting diversity and Vidigal (NCI), and Faustine Williams diversity in the scientific workplace, NIH inclusion. The scholars participate as (NIMHD). Candidates for the DSP launched the Distinguished Scholars a cohort in activities designed to foster are nominated by the NIH ICs that Program (DSP), which facilitates the a sense of belonging and to promote have intramural research programs. hiring and career progression of tenure- research and career success. Nominations for the 2019 cohort of track investigators who have demonstrated They receive mentorship from highly scholars will be due in March 2019. a commitment to promoting diversity experienced NIH senior investigators; Financial support for the DSP and inclusion in the biomedical-research professional leadership training and comes from a central fund of workforce. access to workshops on a variety of contributions made by the ICs, which The DSP aims to reduce the barriers management skills and tactics; and so far have committed support for to the recruitment and success of principal informal networking opportunities three cohorts of scholars. Each scholar investigators from underrepresented with NIH leadership such as the NIH receives research funding from the DSP groups in biomedical research (African- director, institute and center (IC) for the first four years of their tenure- Americans, Hispanics, American Indians, directors, and scientific directors. track appointment; the respective
Load more

Recommended publications
  • Systems-Epigenomics Inference of Transcription Factor Activity
    Chen et al. Genome Biology (2017) 18:236 DOI 10.1186/s13059-017-1366-0 RESEARCH Open Access Systems-epigenomics inference of transcription factor activity implicates aryl- hydrocarbon-receptor inactivation as a key event in lung cancer development Yuting Chen1†, Martin Widschwendter2 and Andrew E. Teschendorff1,2,3*† Abstract Background: Diverse molecular alterations associated with smoking in normal and precursor lung cancer cells have been reported, yet their role in lung cancer etiology remains unclear. A prominent example is hypomethylation of the aryl hydrocarbon-receptor repressor (AHRR) locus, which is observed in blood and squamous epithelial cells of smokers, but not in lung cancer. Results: Using a novel systems-epigenomics algorithm, called SEPIRA, which leverages the power of a large RNA- sequencing expression compendium to infer regulatory activity from messenger RNA expression or DNA methylation (DNAm) profiles, we infer the landscape of binding activity of lung-specific transcription factors (TFs) in lung carcinogenesis. We show that lung-specific TFs become preferentially inactivated in lung cancer and precursor lung cancer lesions and further demonstrate that these results can be derived using only DNAm data. We identify subsets of TFs which become inactivated in precursor cells. Among these regulatory factors, we identify AHR, the aryl hydrocarbon-receptor which controls a healthy immune response in the lung epithelium and whose repressor, AHRR, has recently been implicated in smoking-mediated lung cancer. In addition, we identify FOXJ1, a TF which promotes growth of airway cilia and effective clearance of the lung airway epithelium from carcinogens. Conclusions: We identify TFs, such as AHR, which become inactivated in the earliest stages of lung cancer and which, unlike AHRR hypomethylation, are also inactivated in lung cancer itself.
    [Show full text]
  • Downloaded from USCS Tables (
    bioRxiv preprint doi: https://doi.org/10.1101/318329; this version posted February 4, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The selection arena in early human blastocysts resolves the pluripotent inner cell mass Manvendra Singh1, Thomas J. Widmann2, Vikas Bansal7, Jose L. Cortes2, Gerald G. Schumann3, Stephanie Wunderlich4, Ulrich Martin4, Marta Garcia-Canadas2, Jose L. Garcia- Perez2,5*, Laurence D. Hurst6*#, Zsuzsanna Izsvák1* 1 Max-Delbrück-Center for Molecular Medicine in the Helmholtz Society, Robert-Rössle- Strasse 10, 13125 Berlin, Germany. 2 GENYO. Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, 18016 Granada, Spain. 3 Paul-Ehrlich-Institute, Division of Medical Biotechnology, Paul-Ehrlich-Strasse 51-59, 63225 Langen, Germany. 4Center for Regenerative Medicine Hannover Medical School (MHH) Carl-Neuberg-Str.1, Building J11, D-30625 Hannover, Germany 5Institute of Genetics and Molecular Medicine (IGMM), University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, United Kingdom 6 The Milner Centre for Evolution, Department of Biology and Biochemistry, University of Bath, Bath, Somerset, UK, BA2 7AY. 7 Institute of Medical Systems Biology, Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf (UKE), 20246, Hamburg, Germany. *Corresponding authors *Zsuzsanna Izsvák Max Delbrück Center for Molecular Medicine Robert Rössle Strasse 10, 13092 Berlin, Germany Telefon: +49 030-9406-3510 Fax: +49 030-9406-2547 email: [email protected] http://www.mdcberlin.de/en/research/research_teams/mobile_dna/index.html and *Laurence D.
    [Show full text]
  • Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications
    Stem Cell Rev and Rep DOI 10.1007/s12015-016-9662-8 Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications Behnam Ahmadian Baghbaderani 1 & Adhikarla Syama2 & Renuka Sivapatham3 & Ying Pei4 & Odity Mukherjee2 & Thomas Fellner1 & Xianmin Zeng3,4 & Mahendra S. Rao5,6 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract We have recently described manufacturing of hu- help determine which set of tests will be most useful in mon- man induced pluripotent stem cells (iPSC) master cell banks itoring the cells and establishing criteria for discarding a line. (MCB) generated by a clinically compliant process using cord blood as a starting material (Baghbaderani et al. in Stem Cell Keywords Induced pluripotent stem cells . Embryonic stem Reports, 5(4), 647–659, 2015). In this manuscript, we de- cells . Manufacturing . cGMP . Consent . Markers scribe the detailed characterization of the two iPSC clones generated using this process, including whole genome se- quencing (WGS), microarray, and comparative genomic hy- Introduction bridization (aCGH) single nucleotide polymorphism (SNP) analysis. We compare their profiles with a proposed calibra- Induced pluripotent stem cells (iPSCs) are akin to embryonic tion material and with a reporter subclone and lines made by a stem cells (ESC) [2] in their developmental potential, but dif- similar process from different donors. We believe that iPSCs fer from ESC in the starting cell used and the requirement of a are likely to be used to make multiple clinical products. We set of proteins to induce pluripotency [3]. Although function- further believe that the lines used as input material will be used ally identical, iPSCs may differ from ESC in subtle ways, at different sites and, given their immortal status, will be used including in their epigenetic profile, exposure to the environ- for many years or even decades.
    [Show full text]
  • WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Nazal Polipli Hastalarda Scgb1c1 (Lıgand-Bındıng Proteın Ryd5)
    NAZAL POLİPLİ HASTALARDA SCGB1C1 (LIGAND-BINDING PROTEIN RYD5) GENİNDEKİ MOLEKÜLER PATOLOJİLERİN ARAŞTIRILMASI INVESTIGATION OF MOLECULAR PATHOLOGIES IN SCGB1C1 (LIGAND-BINDING PROTEIN RYD5) GENE IN PATIENTS WITH NASAL POLYPOSIS SİBEL UNURLU ÖZDAŞ PROF.DR. AFİFE İZBIRAK Tez Danışmanı Hacettepe Üniversitesi Lisansüstü Eğitim – Öğretim ve Sınav Yönetmeliğinin Fen Bilimleri Enstitüsü, Biyoloji Anabilim Dalı İçin Öngördüğü DOKTORA TEZİ olarak hazırlanmıştır 2013 NAZAL POLİPLİ HASTALARDA SCGB1C1 (LIGAND-BINDING PROTEIN RYD5) GENİNDEKİ MOLEKÜLER PATOLOJİLERİN ARAŞTIRILMASI INVESTIGATION OF MOLECULAR PATHOLOGIES IN SCGB1C1 (LIGAND-BINDING PROTEIN RYD5) GENE IN PATIENTS WITH NASAL POLYPOSIS SİBEL UNURLU ÖZDAŞ PROF.DR. AFİFE İZBIRAK Tez Danışmanı Hacettepe Üniversitesi Lisansüstü Eğitim – Öğretim ve Sınav Yönetmeliğinin Fen Bilimleri Enstitüsü, Biyoloji Anabilim Dalı İçin Öngördüğü DOKTORA TEZİ olarak hazırlanmıştır 2013 Sibel UNURLU ÖZDAŞ’ın hazırladığı “Nazal Polipli Hastalarda SCGB1C1 (Ligand-Binding Protein RYD5) Genindeki Moleküler Patolojilerin Araştırılması” adlı bu çalışma aşağıdaki jüri tarafından BİYOLOJİ ANABİLİM DALI'nda DOKTORA TEZİ olarak kabul edilmiştir. Başkan (Prof. Dr., Erol AKSÖZ) …………………………….. Danışman (Prof. Dr., Afife İZBIRAK) …………………………….. Üye (Prof. Dr. Hatice MERGEN) …………………………….. Üye (Doç. Dr., Rıza Köksal ÖZGÜL) …………………………….. Üye (Doç. Dr., Selim Sermed ERBEK) …………………………….. Bu tez Hacettepe Üniversitesi Fen Bilimleri Enstitüsü tarafından DOKTORA TEZİ olarak onaylanmıştır. Prof. Dr., Fatma Sevin DÜZ Fen Bilimleri Enstitüsü
    [Show full text]
  • Number 1 January 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology
    Volume 1 - Number 1 May - September 1997 Volume 20 - Number 1 January 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Scope The Atlas of Genetics and Cytogenetics in Oncology and Haematologyis a peer reviewed on-line journal in open access, devoted to genes, cytogenetics, and clinical entities in cancer, and cancer-prone diseases. It is made for and by: clinicians and researchers in cytogenetics, molecular biology, oncology, haematology, and pathology. One main scope of the Atlas is to conjugate the scientific information provided by cytogenetics/molecular genetics to the clinical setting (diagnostics, prognostics and therapeutic design), another is to provide an encyclopedic knowledge in cancer genetics. The Atlas deals with cancer research and genomics. It is at the crossroads of research, virtual medical university (university and post-university e-learning), and telemedicine. It contributes to "meta-medicine", this mediation, using information technology, between the increasing amount of knowledge and the individual, having to use the information. Towards a personalized medicine of cancer. It presents structured review articles ("cards") on: 1- Genes, 2- Leukemias, 3- Solid tumors, 4- Cancer-prone diseases, and also 5- "Deep insights": more traditional review articles on the above subjects and on surrounding topics. It also present 6- Case reports in hematology and 7- Educational items in the various related topics for students in Medicine and in Sciences. The Atlas of Genetics and Cytogenetics in Oncology and Haematology does not publish research articles. See also: http://documents.irevues.inist.fr/bitstream/handle/2042/56067/Scope.pdf Editorial correspondance Jean-Loup Huret, MD, PhD, Genetics, Department of Medical Information, University Hospital F-86021 Poitiers, France phone +33 5 49 44 45 46 [email protected] or [email protected] .
    [Show full text]
  • Signatures of Adaptive Evolution in Platyrrhine Primate Genomes 5 6 Hazel Byrne*, Timothy H
    1 2 Supplementary Materials for 3 4 Signatures of adaptive evolution in platyrrhine primate genomes 5 6 Hazel Byrne*, Timothy H. Webster, Sarah F. Brosnan, Patrícia Izar, Jessica W. Lynch 7 *Corresponding author. Email [email protected] 8 9 10 This PDF file includes: 11 Section 1: Extended methods & results: Robust capuchin reference genome 12 Section 2: Extended methods & results: Signatures of selection in platyrrhine genomes 13 Section 3: Extended results: Robust capuchins (Sapajus; H1) positive selection results 14 Section 4: Extended results: Gracile capuchins (Cebus; H2) positive selection results 15 Section 5: Extended results: Ancestral Cebinae (H3) positive selection results 16 Section 6: Extended results: Across-capuchins (H3a) positive selection results 17 Section 7: Extended results: Ancestral Cebidae (H4) positive selection results 18 Section 8: Extended results: Squirrel monkeys (Saimiri; H5) positive selection results 19 Figs. S1 to S3 20 Tables S1–S3, S5–S7, S10, and S23 21 References (94 to 172) 22 23 Other Supplementary Materials for this manuscript include the following: 24 Tables S4, S8, S9, S11–S22, and S24–S44 1 25 1) Extended methods & results: Robust capuchin reference genome 26 1.1 Genome assembly: versions and accessions 27 The version of the genome assembly used in this study, Sape_Mango_1.0, was uploaded to a 28 Zenodo repository (see data availability). An assembly (Sape_Mango_1.1) with minor 29 modifications including the removal of two short scaffolds and the addition of the mitochondrial 30 genome assembly was uploaded to NCBI under the accession JAGHVQ. The BioProject and 31 BioSample NCBI accessions for this project and sample (Mango) are PRJNA717806 and 32 SAMN18511585.
    [Show full text]
  • Proteomic and Transcriptomic Analysis of Lung Tissue in OVA-Challenged Mice
    Arch. Pharm. Res. Online ISSN 1976-3786 DOI 10.1007/s12272-017-0972-4 Print ISSN 0253-6269 RESEARCH ARTICLE Proteomic and transcriptomic analysis of lung tissue in OVA- challenged mice 1 1 1 1 Yongjin Lee • Yun-Ho Hwang • Kwang-Jin Kim • Ae-Kyung Park • 1 2 3 1 Man-Jeong Paik • Seong Hwan Kim • Su Ui Lee • Sung-Tae Yee • Young-Jin Son1 Received: 16 March 2017 / Accepted: 12 October 2017 Ó The Author(s) 2017. This article is an open access publication Abstract Asthma is a long term inflammatory disease of tissue of OVA challenged moue by RNA-seq. 146 genes the airway of lungs characterized by variable airflow were identified as significantly differentially expressed by obstruction and bronchospasm. Asthma is caused by a OVA treatment, and 118 genes of the 146 differentially complex combination of environmental and genetic inter- expressed genes were up-regulated and 28 genes were actions. In this study, we conducted proteomic analysis of downregulated. These genes were related to inflammation, samples derived from control and OVA challenged mice mucin production, and airway remodeling. The results for environmental respiratory disease by using 2-D gel presented herein enable diagnosis and the identification of electrophoresis. In addition, we explored the genes asso- quantitative markers to monitor the progression of envi- ciated with the environmental substances that cause respi- ronmental respiratory disease using proteomics and geno- ratory disease and conducted RNA-seq by next-generation mic approaches. sequencing. Proteomic analysis revealed 7 up-regulated (keratin KB40, CRP, HSP27, chaperonin containing TCP- Keywords Asthma Á Ovalbumin (OVA) Á Environmental 1, TCP-10, keratin, and albumin) and 3 down-regulated respiratory disease Á Proteomics Á RNA-seq proteins (PLC-a, PLA2, and precursor ApoA-1).
    [Show full text]
  • Novel Computational Analysis of Large Transcriptome Datasets Identifies
    www.nature.com/scientificreports OPEN Novel computational analysis of large transcriptome datasets identifes sets of genes distinguishing chronic obstructive pulmonary disease from healthy lung samples Fabienne K. Roessler1, Birke J. Benedikter2,3, Bernd Schmeck2,4,5,6 & Nadav Bar1* Chronic obstructive pulmonary disease (COPD) kills over three million people worldwide every year. Despite its high global impact, the knowledge about the underlying molecular mechanisms is still limited. In this study, we aimed to extend the available knowledge by identifying a small set of COPD-associated genes. We analysed diferent publicly available gene expression datasets containing whole lung tissue (WLT) and airway epithelium (AE) samples from over 400 human subjects for diferentially expressed genes (DEGs). We reduced the resulting sets of 436 and 663 DEGs using a novel computational approach that utilises a random depth-frst search to identify genes which improve the distinction between COPD patients and controls along the frst principle component of the data. Our method identifed small sets of 10 and 15 genes in the WLT and AE, respectively. These sets of genes signifcantly (p < 10 –20) distinguish COPD patients from controls with high fdelity. The fnal sets revealed novel genes like cysteine rich protein 1 (CRIP1) or secretoglobin family 3A member 2 (SCGB3A2) that may underlie fundamental molecular mechanisms of COPD in these tissues. Abbreviations COPD Chronic obstructive pulmonary disease WLT Whole lung tissue AE Airway epithelium SAE Small airway epithelium FS Former smoker CS Current smoker DEG Diferentially expressed gene PCA Principal component analysis PC1 Principal component 1 RDFS Random depth-frst search SD Standard deviation SEM Standard error of the mean 1Department of Chemical Engineering, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
    [Show full text]
  • Gene Section Review
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Gene Section Review SPINK1 (Serine Peptidase Inhibitor, Kazal Type 1) Hannu Koistinen, Outi Itkonen, Ulf-Hakan Stenman Department of Clinical Chemistry, University of Helsinki (HK,OI, UHS), Laboratory Division HUSLAB, Helsinki University Central Hospital (OI), Helsinki, Finland [email protected]; [email protected]; [email protected] Published in Atlas Database: December 2014 Online updated version : http://AtlasGeneticsOncology.org/Genes/SPINK1ID42375ch5q32.html Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/62508/12-2014-SPINK1ID42375ch5q32.pdf DOI: 10.4267/2042/62503 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology Abstract single Kazal type serine protease inhibitor domain. Review on SPINK1, with data on DNA, on the Description protein encoded, and where the gene is implicated. Maps to chromosomal region 5q32: 147,204,131- Keywords: SPINK1 147,211,349 on reverse (minus) strand (7,219 bp). Gene consists of 4 exons (Horii et al., 1987). Region Identity between 3.8 and 4.0 kb upstream from the translation Other names: PSTI, TATI, SPIK initiation codon contains an interleukin-6 responsive HGNC (Hugo): SPINK1 element (IL6RE) and two potential AP-1 binding sites (Ohmachi et al., 1993; Yasuda et al., 1993). Location: 5q32 CAATCAATAAC sequence (-149 to -139) is a Location (base pair): location 147,204,131- potential pancreas-specific regulatory element 147,211,349 reverse (minus) strand (Human genome (Yasuda et al., 1998).
    [Show full text]
  • Cao Science 2020.Pdf
    RESEARCH ◥ CONCLUSION: The single-cell data resource RESEARCH ARTICLE SUMMARY presented here is notable for its scale, its fo- cus on human fetal development, the breadth HUMAN GENOMICS of tissues analyzed, and the parallel gener- ation of gene expression (this study) and chro- A human cell atlas of fetal gene expression matin accessibility data (Domcke et al.,this issue). We furthermore consolidate the tech- Junyue Cao, Diana R. O’Day, Hannah A. Pliner, Paul D. Kingsley, Mei Deng, Riza M. Daza, nical framework for individual laboratories to Michael A. Zager, Kimberly A. Aldinger, Ronnie Blecher-Gonen, Fan Zhang, Malte Spielmann, generate and analyze gene expression and James Palis, Dan Doherty, Frank J. Steemers, Ian A. Glass, Cole Trapnell*, Jay Shendure* chromatin accessibility data from millions of single cells. Looking forward, we envision that the somewhat narrow window of mid- INTRODUCTION: A reference atlas of human cell 72 to 129 days in estimated postconceptual age gestational human development studied here typesisamajorgoalforthefield.Here,weset and representing 15 organs, altogether profiling will be complemented by additional atlases out to generate single-cell atlases of both gene 4 million single cells. We developed and applied of earlier and later time points, as well as expression (this study) and chromatin acces- a framework for quantifying cell type specificity, similarly comprehensive profiling and inte- sibility (Domcke et al., this issue) using diverse identifying 657 cell subtypes, which we prelimi- gration of data from model organisms. The human tissues obtained during midgestation. narily annotated based on cross-matching to continued development and application of mouse cell atlases.
    [Show full text]
  • Full Text (PDF)
    Published OnlineFirst September 18, 2018; DOI: 10.1158/2159-8290.CD-17-0987 RESEARCH ARTICLE Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin Dian Yang1,2,3, Sarah K. Denny2,4, Peyton G. Greenside5, Andrea C. Chaikovsky1,2,3, Jennifer J. Brady2, Youcef Ouadah1,6, Jeffrey M. Granja2,4, Nadine S. Jahchan2,3, Jing Shan Lim1,2,3, Shirley Kwok7, Christina S. Kong7, Anna S. Berghoff8,9,10, Anna Schmitt11, H. Christian Reinhardt11,12,13, Kwon-Sik Park14, Matthias Preusser9,10, Anshul Kundaje2,15, William J. Greenleaf2, Julien Sage1,2,3, and Monte M. Winslow1,2,7 Downloaded from cancerdiscovery.aacrjournals.org on September 27, 2021. © 2018 American Association for Cancer Research. Published OnlineFirst September 18, 2018; DOI: 10.1158/2159-8290.CD-17-0987 ABSTRACT The extent to which early events shape tumor evolution is largely uncharacterized, even though a better understanding of these early events may help identify key vul- nerabilities in advanced tumors. Here, using genetically defi ned mouse models of small cell lung cancer (SCLC), we uncovered distinct metastatic programs attributable to the cell type of origin. In one model, tumors gain metastatic ability through amplifi cation of the transcription factor NFIB and a widespread increase in chromatin accessibility, whereas in the other model, tumors become metastatic in the absence of NFIB-driven chromatin alterations. Gene-expression and chromatin accessibility analyses identify distinct mechanisms as well as markers predictive of metastatic progression in both groups. Underlying the difference between the two programs was the cell type of origin of the tumors, with NFIB- independent metastases arising from mature neuroendocrine cells.
    [Show full text]